About CervoMed Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://cervomed.com/
Frequently Asked Questions
What is the 52-week range for CRVO?
The 52-week high is $10 and the 52-week low is $2.13.
What is the P/E ratio for CRVO?
The P/E ratio data is currently unavailable.
What is the dividend yield for CRVO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -156.02%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1056.59%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.01.
Analyst Recommendation Trends
Wall Street analyst consensus for CRVO over the last few months:
Latest CRVO News
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future clinical trials CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. ("CervoMed" or the "Company") (N
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026. Panel DetailsTitle: "Frontiers in Neuroscience"Date: Tuesday, September 29
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an ora
CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology,
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1x1 Investor MeetingsDate: Friday, September 11, 2026Time: 10:55 – 11:25 AM ET Webcast Link: https://sqps.onstreamsec
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-11 | BOGER JOSHUA S | +955,414 | - | - |
| 2026-06-11 | BOGER JOSHUA S | +955,414 | - | - |
| 2026-06-11 | BOGER JOSHUA S | +955,414 | $3.14 | $3,000,000 |
| 2026-06-08 | ZAVRL FRANK | +8,150 | - | - |
| 2026-06-08 | Sabbagh Marwan | +8,150 | - | - |
| 2026-06-08 | Quigley David | +8,150 | - | - |
| 2026-06-08 | Poulton Jeffrey V. | +8,150 | - | - |
| 2026-06-08 | Hollingsworth Jane H | +8,150 | - | - |
| 2026-06-08 | Gregoire Sylvie | +8,150 | - | - |
| 2026-06-08 | BOGER JOSHUA S | +8,150 | - | - |
| 2026-06-08 | ALAM JOHN J | +8,150 | - | - |
| 2026-02-11 | Winton Matthew | +30,000 | - | - |
| 2026-02-11 | Gregoire Sylvie | +75,000 | - | - |
| 2026-02-11 | ELDER WILLIAM ROBERT | +30,000 | - | - |
| 2026-02-11 | De Rosch Mark | +30,000 | - | - |
| 2026-02-11 | Blackburn Kelly | +30,000 | - | - |
| 2026-02-11 | ALAM JOHN J | +75,000 | - | - |
| 2025-11-18 | Winton Matthew | +1,500 | $7.95 | $11,925 |
| 2025-11-18 | ELDER WILLIAM ROBERT | +2,500 | $8.32 | $20,800 |
| 2025-11-17 | Winton Matthew | +3,500 | $8.43 | $29,505 |
| 2025-11-17 | Gregoire Sylvie | +10,807 | $8.46 | $91,427 |
| 2025-11-17 | Gregoire Sylvie | +10,793 | $8.46 | $91,309 |
| 2025-11-17 | ELDER WILLIAM ROBERT | +1,000 | $8.45 | $8,450 |
| 2025-11-17 | ALAM JOHN J | +10,793 | $8.46 | $91,309 |
| 2025-11-17 | ALAM JOHN J | +10,807 | $8.46 | $91,427 |
| 2025-11-14 | Gregoire Sylvie | +1,693 | $7.55 | $12,782 |
| 2025-11-14 | Gregoire Sylvie | +1,707 | $7.57 | $12,922 |
| 2025-11-14 | ALAM JOHN J | +1,707 | $7.57 | $12,922 |
| 2025-11-14 | ALAM JOHN J | +1,693 | $7.55 | $12,782 |
| 2025-11-14 | Winton Matthew | +10,000 | $7.57 | $75,700 |
| 2025-11-13 | Gregoire Sylvie | +4,447 | $7.51 | $33,397 |
| 2025-11-13 | ALAM JOHN J | +4,447 | $7.51 | $33,397 |
| 2025-11-12 | Gregoire Sylvie | +5,553 | $7.35 | $40,815 |
| 2025-11-12 | ELDER WILLIAM ROBERT | +3,500 | $7.44 | $26,040 |
| 2025-11-12 | ALAM JOHN J | +5,553 | $7.35 | $40,815 |
| 2025-10-27 | Quigley David | +16,200 | - | - |
| 2025-10-06 | Winton Matthew | +75,000 | - | - |